Edition:
United Kingdom

Therapix Biosciences Ltd (TRPX.OQ)

TRPX.OQ on NASDAQ Stock Exchange Capital Market

5.45USD
16 Feb 2018
Change (% chg)

$-0.01 (-0.18%)
Prev Close
$5.46
Open
$5.46
Day's High
$5.48
Day's Low
$5.34
Volume
541
Avg. Vol
8,120
52-wk High
$10.90
52-wk Low
$4.42

Select another date:

Wed, Feb 7 2018

BRIEF-Therapix Biosciences Expects To Test THX-110 In Early Study In Q2

* THERAPIX BIOSCIENCES LTD - EXPECT TO EVALUATE THX-110 IN A PHASE IIB CLINICAL STUDY IN Q2 OF 2018

BRIEF-Therapix Biosciences Announces Expansion Into Precision Medicine Through New Fully-Owned Subsidiary

* THERAPIX BIOSCIENCES ANNOUNCES EXPANSION INTO PRECISION MEDICINE THROUGH NEW FULLY-OWNED SUBSIDIARY AND PROVIDES CORPORATE UPDATE TODAY AT THE BIOTECH SHOWCASE™ 2018

BRIEF-Therapix Biosciences and Co's CFO Entered Into A "Mutually-Amicable" Separation Agreement

* THERAPIX BIOSCIENCES SAYS CO AND CFO JOSH BLACHER ENTERED INTO A "MUTUALLY-AMICABLE" SEPARATION AGREEMENT ON DECEMBER 19 - SEC FILING

Therapix expects to have results of Tourette's drug trial by end of first quarter

TEL AVIV Israel's Therapix Biosciences said on Monday it expects by the end of March to have the results from its mid-stage trial of a cannabinoid-based drug for treating Tourette's syndrome which could be worth billions of dollars in revenues.

Therapix expects to have results of Tourette's drug trial by end of Q1

TEL AVIV, Dec 4 Israel's Therapix Biosciences said on Monday it expects by the end of March to have the results from its mid-stage trial of a cannabinoid-based drug for treating Tourette's syndrome which could be worth billions of dollars in revenues.

BRIEF-Therapix Biosciences plans preclinical study to evaluate opioid-sparing effects of two innovative synthetic cannabinoids

* Therapix Biosciences Ltd plans preclinical study to evaluate opioid-sparing effects of two innovative synthetic cannabinoids Source text for Eikon: Further company coverage:

BRIEF-Therapix Biosciences Q3 loss per share $0.30

* Therapix Biosciences reports third quarter 2017 financial results and provides business update

BRIEF-Therapix Biosciences' board chairman, Ascher Shmulewitz, appointed as interim chief executive officer

* Therapix Biosciences' board chairman, Ascher Shmulewitz, appointed as interim chief executive officer Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Therapix initiates non-clinical studies for its antibacterial program

* Therapix- Initiated non-clinical studies to evaluate efficacy of compound THX-150 with Weizmann Institute of Science & Tel Aviv Sourasky Medical Center​

BRIEF-Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea

* Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Select another date: